<DOC>
	<DOC>NCT00803686</DOC>
	<brief_summary>This study is being conducted to assess the plasma CTx-1 concentrations when dosing is at night and to compare these results with those obtained with a placebo control and with commercially available nasal calcitonin.</brief_summary>
	<brief_title>A Study of Oral Calcitonin Given at Night to Healthy Postmenopausal Women</brief_title>
	<detailed_description>Timing of the dose of recombinant salmon calcitonin (rsCT) is important in effecting reduction of osteoclast activity. It is theorized that a dose administered before bedtime will be more effective than a dose administered in the morning. See protocol summary for information.</detailed_description>
	<mesh_term>Salmon calcitonin</mesh_term>
	<mesh_term>Calcitonin</mesh_term>
	<mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
	<criteria>Inclusion Criteria Postmenopausal female, in good health (at least five years since last menses). Age greater than or equal to 45 years old and less than or equal to 70 years old Weight Â± 20% of the Metropolitan Life weight table. Plasma CTx1 greater than or equal to 0.25 ng/ml. Total calcium, phosphorus, and magnesium within normal range. Willing and able to comply with all study requirements. Willing and able to sign written informed consent. Negative urine pregnancy test at screening. Negative Screen for Hepatitis B and C, HIV and drugs of abuse. History of parathyroid, thyroid, pituitary or adrenal diseases. History of musculoskeletal disease. History of gastroesophageal reflux disease (GERD) or other significant gastrointestinal disorders. History of cancer within 5 years of enrollment other than basal cell carcinoma. History of regular use of a NonSteroidal Antiinflammatory Drug (NSAID). History of surgery within 60 days of enrollment. History of hypersensitivity or allergies (other than seasonal allergies) within years of enrollment including known sensitivity to the active ingredients or the excipients in the study medications. Use of concomitant medications other than acetaminophen within 7 days of enrollment or anticipated need to use such concomitant medications during the study. Use of bisphosphonates within 6 months, SERMS, estrogen or estrogenlike drugs 2 months, or calcitonin 1 month. Presence of any clinically significant illness. Unwilling or unable to comply with all study requirements. Unwilling or unable to sign written, informed consent. History of drug or alcohol abuse. Participation in any clinical study of an investigational drug within 60 days of enrollment. Plasma CTx1 less than 0.25 ng/mL.</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>